Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20374838 | 0.88 | TAAR1 (0.52) | MEN1KMT2APYCR1KDM4ESMN1; SMN2 | |
| SCHEMBL2580840 | 0.86 | PYCR1 (0.48) | MEN1KMT2APYCR1KDM4ESMN1; SMN2 | |
| SCHEMBL2578168 | 0.86 | PYCR1 (0.45) | MEN1KMT2APYCR1KDM4ESMN1; SMN2 | |
| SCHEMBL4033029 | 0.82 | PYCR1 (0.46) | MEN1KMT2APYCR1CYP1A2CYP3A4 | |
| SCHEMBL2568705 | 0.81 | MEN1 (0.55) | MEN1KMT2APYCR1KDM4ESMN1; SMN2 | |
| SCHEMBL2568962 | 0.80 | HTT (0.52) | MEN1KMT2APYCR1KDM4ESMN1; SMN2 | |
| SCHEMBL4029586 | 0.80 | SLC6A4 (0.56) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10972042 | 0.77 | CHRNB2 (0.54) | MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2655848 | 0.77 | PYCR1 (0.59) | PYCR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5964000 | 0.77 | CNR2 (0.60) | MEN1KMT2AKDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3939964-A1 | COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939964-A1 | COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-1465870-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINIUM SALTS, METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT AND MEDICAMENTS COMPRISING THE SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-03 | — | — | EP | disclosed |
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1465870-A2 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINIUM SALTS, METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT AND MEDICAMENTS COMPRISING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1453810-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-6703405-B2 | RESPIRATORY SYSTEM AND SLEEP DISORDERS; HPOTENSIVE AGENTS; ANTIISCHEMIC, ANTISTROKE, ANTIEDEMA, ANTISTROKE, ANTICARCINOGENIC, AND ANTIDIABETIC AGENTS; ATHEROSCLEROSIS, GALLSTONE TREATMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-09 | — | — | US | disclosed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| US-20030171580-A1 | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003055880-A2 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINIUM SALTS, METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT AND MEDICAMENTS COMPRISING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003048129-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | MEN1 4705/4885KMT2A 3647/4885PYCR1 2553/4885 |
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | MEN1 2959/4885KMT2A 3056/4885PYCR1 548/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | MEN1 4705/4885KMT2A 3647/4885PYCR1 2553/4885 |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | MEN1 4705/4885KMT2A 3647/4885PYCR1 2553/4885 |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | MEN1 3017/4885KMT2A 2664/4885PYCR1 523/4885 |
| US-20030171580-A1 | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, REN | MEN1 2747/4885KMT2A 2944/4885PYCR1 700/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | MEN1 4705/4885KMT2A 3647/4885PYCR1 2553/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | MEN1 4705/4885KMT2A 3647/4885PYCR1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.